Edition:
United States

Clearside Biomedical Inc (CLSD.OQ)

CLSD.OQ on NASDAQ Stock Exchange Global Market

7.05USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$7.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
42,882
52-wk High
$10.46
52-wk Low
$5.44

Latest Key Developments (Source: Significant Developments)

Clearside Biomedical Q3 loss per share $0.72
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Clearside Biomedical Inc ::Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.72.Q3 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.  Full Article

Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA
Tuesday, 24 Oct 2017 04:30pm EDT 

Oct 24 (Reuters) - Clearside Biomedical Inc :Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA used together with Eylea in patients with diabetic macular edema.Clearside Biomedical Inc - ‍patient follow-up in Tybee trial is 6 months​.  Full Article

Clearside Biomedical reports Q2 loss per share $0.54
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Clearside Biomedical Inc :Announces second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.54.Q2 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Clearside biomedical - ‍cash, cash equivalents and short-term investments totaled $66.0 million as of june 30, compared to $83.6 million as of dec 31, 2016​.  Full Article

Clearside Biomedical completes patient enrollment in Phase 3 Peachtree Clinical Trial of CLS-TA
Monday, 7 Aug 2017 08:00am EDT 

Aug 7 (Reuters) - Clearside Biomedical Inc ::Announces completion of patient enrollment in pivotal Phase 3 Peachtree Clinical Trial of CLS-TA for Suprachoroidal administration in patients with Macular Edema associated with non-infectious Uveitis.Co currently expects to report top-line results from trial in Q1 of 2018.  Full Article

Clearside Biomedical announces first patient randomized in phase 2 clinical trial of CLS-TA
Tuesday, 11 Jul 2017 04:30pm EDT 

July 11 (Reuters) - Clearside Biomedical Inc :Clearside Biomedical announces first patient randomized in phase 2 clinical trial of cls-ta used together with eylea in patients with diabetic macular edema.Clearside Biomedical Inc - currently expect to report three-month preliminary data in first half of 2018.  Full Article

Clearside Biomedical files for mixed shelf offering of up to $250 mln - SEC Filing‍​ ‍​
Monday, 3 Jul 2017 06:25am EDT 

July 3 (Reuters) - Clearside Biomedical Inc :Clearside Biomedical Inc files for mixed shelf offering of up to $250 million - SEC Filing‍​ ‍​.  Full Article

Clearside Biomedical ‍on June 30, entered into sales agreement with Cowen and Company, LLC - SEC Filing​
Monday, 3 Jul 2017 06:24am EDT 

July 3 (Reuters) - Clearside Biomedical Inc :Clearside Biomedical Inc - ‍on June 30, 2017, Clearside Biomedical, Inc. entered into sales agreement with Cowen and Company, LLC - SEC Filing​.Clearside Biomedical- ‍agreement to offer, sell shares of common stock having aggregate offering price of up to $50 million through Cowen as sales agent​.  Full Article

Clearside Biomedical Q1 loss per share $0.41
Wednesday, 10 May 2017 07:00am EDT 

May 10 (Reuters) - Clearside Biomedical Inc :Clearside biomedical, inc. Announces first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.41.Q1 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.Clearside biomedical inc- qtrly research & development expenses for three months ended march 31, 2017 were $7.6 million, compared to $4.6 million for q1 of 2016.  Full Article

Clearside Biomedical provides update on diabetic macular edema trial
Thursday, 20 Apr 2017 08:00am EDT 

April 20 (Reuters) - Clearside Biomedical Inc :Clearside biomedical, inc. Announces completion of patient enrollment in phase 1/2 open label clinical trial of cls-ta in diabetic macular edema.Currently expects to report preliminary results from exploratory clinical trial of cls-ta in second half of 2017.  Full Article

Clearside Biomedical reports Q4 loss per share $0.45
Tuesday, 14 Mar 2017 07:30am EDT 

Clearside Biomedical Inc : Clearside Biomedical Inc announces fourth quarter and full year 2016 financial results . Q4 loss per share $0.45 . Q4 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S .Cash, cash equivalents and short-term investments totaled $83.6 million as of December 31, 2016.  Full Article

BRIEF-Clearside Biomedical Q3 loss per share $0.72

* Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update